Hikma Pharmaceuticals PLC (LON:HIK)
1,437.00
+15.00 (1.05%)
May 14, 2026, 8:21 AM GMT
Hikma Pharmaceuticals Revenue
In the year 2025, Hikma Pharmaceuticals had annual revenue of $3.35B USD with 7.10% growth. Hikma Pharmaceuticals had revenue of $1.69B in the half year ending December 31, 2025, with 16.78% growth.
Revenue
$3.35B
Revenue Growth
+7.10%
P/S Ratio
1.23
Revenue / Employee
$356.28K
Employees
9,400
Market Cap
3.06B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.35B | 222.00M | 7.10% |
| Dec 31, 2024 | 3.13B | 252.00M | 8.77% |
| Dec 31, 2023 | 2.88B | 358.00M | 14.22% |
| Dec 31, 2022 | 2.52B | -36.00M | -1.41% |
| Dec 31, 2021 | 2.55B | 212.00M | 9.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Haleon | 11.03B |
| HUTCHMED (China) | 407.54M |
| ECO Animal Health Group | 85.81M |
| Allergy Therapeutics | 57.29M |
| Shield Therapeutics | 36.93M |
| Venture Life Group | 35.17M |
| Provexis | 871.27K |
| Chill Brands Group | 370.50K |
Hikma Pharmaceuticals News
- 20 days ago - Hikma Pharmaceuticals Transcript: Trading update - Transcripts
- 21 days ago - UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war - Reuters
- 2 months ago - Hikma Pharmaceuticals price target lowered to 2,000 GBp from 2,400 GBp at JPMorgan - TheFly
- 2 months ago - Hikma Pharmaceuticals Earnings Call Transcript: H2 2025 - Transcripts
- 2 months ago - Hikma Pharmaceuticals Earnings Call Transcript: H2 2025 - Transcripts
- 4 months ago - Hikma Pharmaceuticals downgraded to Underweight at Barclays amid uncertainty - TheFly
- 4 months ago - Hikma Pharmaceuticals downgraded to Underweight from Equal Weight at Barclays - TheFly
- 5 months ago - Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US - PRNewsWire